ICH Q/S/E/M Guideline Categories (Quality, Safety, Efficacy, Multidisciplinary)

The International Council for Harmonisation (ICH) organizes every technical guideline it publishes into four categories, identified by a single letter: Quality (Q), Safety (S), Efficacy (E), and Multidisciplinary (M). This structure is the primary way research administrators, regulatory affairs staff, and clinical trial teams navigate the ICH guideline library — knowing which letter governs a given activity is the first step to finding the right guideline. See the dedicated ICH (International Council for Harmonisation) entry for background on the organization itself; this page focuses on the four-category taxonomy and how individual guidelines are numbered within it.

The four categories

Quality (Q)

Quality guidelines address pharmaceutical development, manufacturing, and product quality across a medicine’s lifecycle — stability testing, impurity thresholds, Good Manufacturing Practice (GMP) risk management, and pharmaceutical development approaches. ICH Q1 (Stability Testing) is a representative example, and ICH Q7 addresses GMP specifically for Active Pharmaceutical Ingredients (APIs).

Safety (S)

Safety guidelines govern nonclinical (in vitro and animal) safety testing conducted before and alongside human trials — carcinogenicity, genotoxicity, and reproductive toxicity (reprotoxicity) studies, among others. These studies generate the nonclinical safety package that supports a decision to proceed into, or continue, human dosing.

Efficacy (E)

Efficacy guidelines cover the design, conduct, safety monitoring, and reporting of clinical trials in humans — this is the category most directly relevant to day-to-day clinical trial operations and research administration. ICH E6(R2) (Good Clinical Practice) is the best-known guideline in this series, and it has since been superseded as the current core revision by ICH E6(R3), finalized in January 2025; institutions and sponsors should confirm which revision a given protocol or contract references, since both remain in active use during the transition. See also the general ICH GCP (Good Clinical Practice) entry for what the guideline requires independent of revision number.

Multidisciplinary (M)

Multidisciplinary guidelines cover cross-cutting topics that don’t sort uniquely into Quality, Safety, or Efficacy — most notably the Common Technical Document (CTD, ICH M4), the standardized format used to assemble a marketing application dossier for submission to multiple regulators, and MedDRA (the Medical Dictionary for Regulatory Activities), the standardized terminology ICH maintains for coding adverse events and other clinical data. Electronic Standards for the Transfer of Regulatory Information (ESTRI) also falls under this category.

How individual guidelines are numbered

Within each category, guidelines are numbered sequentially (Q1, Q2, Q3 …; S1, S2 …; E1, E2 …; M1, M2 …), and a guideline that has been substantively revised carries a parenthetical revision marker after its number — for example E6(R1), E6(R2), and E6(R3) are three successive revisions of the same core Good Clinical Practice guideline, not three separate guidelines. Always cite the full designation, including the revision marker where one exists, since requirements can change meaningfully between revisions (E6(R3), for instance, introduces a more explicitly risk-based, principles-oriented structure compared to E6(R2)).

A document only counts as an adopted ICH guideline once it has passed through ICH’s multi-step development process to Step 4 (adoption by the ICH Assembly); guidelines at earlier steps are drafts open for regional regulatory consultation, not yet binding reference points for the categories above.

Why the taxonomy matters for research administration

Because Quality, Safety, and Efficacy guidelines each govern a distinct phase and function of drug development, a single clinical development programme typically touches all four categories at once: Q-series guidance shapes how the investigational product itself is manufactured and characterized, S-series guidance shapes the nonclinical safety package that justifies first-in-human dosing, E-series guidance shapes how the clinical trials themselves are designed, conducted, monitored, and reported, and M-series guidance shapes how the resulting evidence is packaged and coded for submission. Research administrators coordinating a multi-site or multinational trial benefit from knowing which category a given requirement falls under, both to locate the governing guideline quickly and to understand why a requirement exists (a manufacturing question is a Q-series concern; an informed-consent or monitoring question is typically an E-series concern).